150 related articles for article (PubMed ID: 31261592)
41. Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals.
Kono M; Nishida N; Hagiwara S; Minami T; Chishina H; Arizumi T; Minaga K; Kamata K; Komeda Y; Sakurai T; Takenaka M; Takita M; Yada N; Ida H; Minami Y; Ueshima K; Watanabe T; Kudo M
Dig Dis; 2017; 35(6):556-564. PubMed ID: 29040988
[TBL] [Abstract][Full Text] [Related]
42. Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
Sølund C; Pedersen MS; Fahnøe U; Filskov J; Jenssen H; Weis N; Schønning K; Bukh J
APMIS; 2023 Aug; 131(8):426-433. PubMed ID: 37355962
[TBL] [Abstract][Full Text] [Related]
43. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
Paolucci S; Premoli M; Novati S; Gulminetti R; Maserati R; Barbarini G; Sacchi P; Piralla A; Sassera D; De Marco L; Girello A; Mondelli MU; Baldanti F
Sci Rep; 2017 Nov; 7(1):16017. PubMed ID: 29167469
[TBL] [Abstract][Full Text] [Related]
44. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Rajender Reddy K; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
J Hepatol; 2019 Sep; 71(3):486-497. PubMed ID: 31096006
[TBL] [Abstract][Full Text] [Related]
45. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
46. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
[TBL] [Abstract][Full Text] [Related]
47. Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life.
Real LM; Macías J; Pérez AB; Merino D; Granados R; Morano L; Delgado M; Ríos MJ; Galera C; Deltoro MG; Merchante N; García F; Pineda JA
Sci Rep; 2018 Oct; 8(1):14905. PubMed ID: 30297726
[TBL] [Abstract][Full Text] [Related]
48. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
[TBL] [Abstract][Full Text] [Related]
49. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of hepatitis C antiviral treatment and feasibility of hepatitis C elimination goal.
Burgui C; San Miguel R; Goñi-Esarte S; Juanbeltz R; Úriz-Otano JI; Reparaz J; Sarobe M; Zozaya JM; Castilla J
Postgrad Med; 2023 May; 135(4):352-360. PubMed ID: 36305320
[TBL] [Abstract][Full Text] [Related]
51. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
52. Baseline resistance-associated substitutions may impact DAA response among treatment failure chronic hepatitis C patients with pegylated interferon and ribavirin in real life.
Ren S; Wei F; Jin Y; Lu J; He Z; Ma L; Zheng Y; Wang J; Chen X
Antivir Ther; 2020; 25(5):245-255. PubMed ID: 32936785
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
[TBL] [Abstract][Full Text] [Related]
54. 12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
Degasperi E; Aghemo A; Paolucci S; D'Ambrosio R; Borghi M; Perbellini R; Novazzi F; De Nicola S; Lunghi G; Baldanti F; Lampertico P
Dig Liver Dis; 2018 Jul; 50(7):703-706. PubMed ID: 29499903
[TBL] [Abstract][Full Text] [Related]
55. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
[TBL] [Abstract][Full Text] [Related]
56. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
[TBL] [Abstract][Full Text] [Related]
57. Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up.
Badia Aranda E; Fernández Marcos C; Puebla Maestu A; Gozalo Marín V; Vinuesa Campo R; Calvo Simal S; Gómez Camarero J
Gastroenterol Hepatol; 2022 Dec; 45(10):767-779. PubMed ID: 35189262
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
Hill DD; Kramer JR; Chaffin KR; Mast TC; Robertson MN; Kanwal F; Haber BA
Ann Hepatol; 2023; 28(2):100899. PubMed ID: 36632975
[TBL] [Abstract][Full Text] [Related]
59. Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4.
Bach TA; Zaiken K
J Manag Care Spec Pharm; 2016 Dec; 22(12):1437-1445. PubMed ID: 27882839
[TBL] [Abstract][Full Text] [Related]
60. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
